Last reviewed · How we verify
NCT05549453
Use of Nexstim SNBT System
NA trial testing Nexstim SNBT use in Usability of the Graphical User Interface of the Device for Its Intended Use in 12 participants. Completed in 31 December 2023.
31 December 2022
Quick facts
| Lead sponsor | Nexstim Ltd |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | device feasibility |
| Enrollment | 12 |
| Start date | 26 September 2022 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Finland |
Drugs / interventions tested
- Nexstim SNBT use
Conditions studied
- Usability of the Graphical User Interface of the Device for Its Intended Use — all drugs for Usability of the Graphical User Interface of the Device for Its Intended Use →
Sponsor
Nexstim Ltd
Who can join
Adults 18 to 64, any sex, with Usability of the Graphical User Interface of the Device for Its Intended Use. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The clinical investigation assesses the usability of the new graphical user interface of the Nexstim SNBT device in its intended clinical uses. The hardware and the technical functionality of the device of the SNBT device are in other respects similar to those of the earlier Nexstim NBT device, which has been cleared by FDA for treatment of Major Depressive Disorder in 2017 (K170902) and has received EU CE mark for the same and for treatment of chronic neuropathic pain. The present investigation is not intended to establish the safety and efficacy of the SNBT device. Rather, the purpose is to assess the usability of the new user interface in a feasibility study conducted with a prototype device utilizing the new user interface.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05549453
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Nexstim Ltd trials
Trials by the same sponsor.
- NCT03010462 — Electric Field Navigated 1hz Rtms for Post-stroke Motor Recovery Trial · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05549453 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nexstim Ltd
- Last refreshed: 18 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05549453.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing